AstraZeneca's Camille Hertzka Discusses Interim PROpel Trial Findings in mCRPC
February 25th 2022, 11:30pm
VideoCamille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).